Myovant Sciences (NYSE:MYOV) issued its earnings results on Thursday. The company reported ($0.99) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.93) by ($0.06), Fidelity Earnings reports.
Shares of MYOV stock opened at $19.06 on Friday. The company has a market cap of $1.46 billion, a P/E ratio of -7.91 and a beta of 0.12. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.07 and a current ratio of 3.07. Myovant Sciences has a 52-week low of $11.30 and a 52-week high of $27.45.
In other Myovant Sciences news, Director Mark Altmeyer acquired 3,500 shares of the business’s stock in a transaction that occurred on Saturday, November 17th. The shares were bought at an average cost of $13.38 per share, with a total value of $46,830.00. Following the completion of the acquisition, the director now directly owns 3,500 shares in the company, valued at approximately $46,830. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 3.10% of the company’s stock.
A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. assumed coverage on shares of Myovant Sciences in a research report on Thursday, September 13th. They set an “overweight” rating and a $39.00 target price on the stock. Zacks Investment Research raised shares of Myovant Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, October 10th. Cowen reaffirmed a “buy” rating on shares of Myovant Sciences in a research report on Friday. Finally, Goldman Sachs Group assumed coverage on shares of Myovant Sciences in a research report on Friday, October 26th. They set a “neutral” rating and a $25.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Myovant Sciences presently has a consensus rating of “Buy” and a consensus target price of $29.20.
COPYRIGHT VIOLATION NOTICE: “Myovant Sciences (MYOV) Releases Earnings Results, Misses Estimates By $0.06 EPS” was first reported by Stock Observer and is the sole property of of Stock Observer. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.thestockobserver.com/2018/11/10/myovant-sciences-myov-releases-earnings-results-misses-estimates-by-0-06-eps.html.
Myovant Sciences Company Profile
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
Read More: Diversification
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.